Literature DB >> 23761155

Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method.

Emilia Cantón1, Javier Pemán, Carmen Iñiguez, David Hervás, Jose L Lopez-Hontangas, Cidalia Pina-Vaz, Juan J Camarena, Isolina Campos-Herrero, Inmaculada García-García, Ana M García-Tapia, Remedios Guna, Paloma Merino, Luisa Pérez del Molino, Carmen Rubio, Anabel Suárez.   

Abstract

In the absence of clinical breakpoints (CBP), epidemiological cutoff values (ECVs) are useful to separate wild-type (WT) isolates (without mechanisms of resistance) from non-WT isolates (those that can harbor some resistance mechanisms), which is the goal of susceptibility tests. Sensititre YeastOne (SYO) is a widely used method to determine susceptibility of Candida spp. to antifungal agents. The CLSI CBP have been established, but not for the SYO method. The ECVs for four azoles, obtained using MIC distributions determined by the SYO method, were calculated via five methods (three statistical methods and based on the MIC50 and modal MIC). Respectively, the median ECVs (in mg/liter) of the five methods for fluconazole, itraconazole, posaconazole, and voriconazole (in parentheses: the percentage of isolates inhibited by MICs equal to or less than the ECVs; the number of isolates tested) were as follows: 2 (94.4%; 944), 0.5 (96.7%; 942), 0.25 (97.6%; 673), and 0.06 (96.7%; 849) for Candida albicans; 4 (86.1%; 642), 0.5 (99.4%; 642), 0.12 (93.9%; 392), and 0.06 (86.9%; 559) for C. parapsilosis; 8 (94.9%; 175), 1 (93.7%; 175), 2 (93.6%; 125), and 0.25 (90.4%; 167) for C. tropicalis; 128 (98.6%; 212), 4 (95.8%; 212), 4 (96.0%; 173), and 2 (98.5; 205) for C. glabrata; 256 (100%; 53), 1 (98.1%; 53), 1 (100%; 33), and 1 (97.9%; 48) for C. krusei; 4 (89.2%; 93), 0.5 (100%; 93), 0.25 (100%; 33), and 0.06 (87.7%; 73) for C. orthopsilosis. All methods included ≥94% of isolates and yielded similar ECVs (within 1 dilution). These ECVs would be suitable for monitoring emergence of isolates with reduced susceptibility by using the SYO method.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23761155      PMCID: PMC3719635          DOI: 10.1128/JCM.01230-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Comparison of the Sensititre YeastOne colorimetric microdilution panel and the NCCLS broth microdilution method for antifungal susceptibility testing against Candida species.

Authors:  Samuel Bernal; Ana Isabel Aller; Mónica Chávez; Anastasio Valverde; Carmen Serrano; M Jesús Gutiérrez; G Quindós; Estrella Martín Mazuelos
Journal:  Chemotherapy       Date:  2002-03       Impact factor: 2.544

2.  Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; N Holliday; S B Killian
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

3.  Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.

Authors:  Barbara D Alexander; Terry C Byrne; Kelly L Smith; Kimberly E Hanson; Kevin J Anstrom; John R Perfect; L Barth Reller
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

4.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

Authors:  J Turnidge; G Kahlmeter; G Kronvall
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

5.  Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model.

Authors:  D Pittet; N Li; R F Woolson; R P Wenzel
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

6.  Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne method.

Authors:  Emilia Cantón; Javier Pemán; David Hervás; Carmen Iñiguez; David Navarro; Julia Echeverría; José Martínez-Alarcón; Dionisia Fontanals; Bárbara Gomila-Sard; Buenaventura Buendía; Luis Torroba; Josefina Ayats; Angel Bratos; Ferran Sánchez-Reus; Isabel Fernández-Natal
Journal:  J Clin Microbiol       Date:  2012-09-26       Impact factor: 5.948

7.  Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.

Authors:  Juan Luis Rodriguez-Tudela; Laura Alcazar-Fuoli; Emilia Mellado; Ana Alastruey-Izquierdo; Araceli Monzon; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

Review 8.  Nosocomial fungal infections: epidemiology, diagnosis, and treatment.

Authors:  Joshua Perlroth; Bryan Choi; Brad Spellberg
Journal:  Med Mycol       Date:  2007-06       Impact factor: 4.076

9.  Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes.

Authors:  Elisabete Ricardo; Sofia Costa-de-Oliveira; Ana Silva Dias; José Guerra; Acácio Gonçalves Rodrigues; Cidália Pina-Vaz
Journal:  FEMS Yeast Res       Date:  2009-03-30       Impact factor: 2.796

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

View more
  14 in total

1.  Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.

Authors:  Maria Siopi; Aikaterini Tarpatzi; Eleni Kalogeropoulou; Sofia Damianidou; Alexandra Vasilakopoulou; Sophia Vourli; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; M A Pfaller; B Bustamante; E Canton; A Fothergill; J Fuller; G M Gonzalez; C Lass-Flörl; S R Lockhart; E Martin-Mazuelos; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M W Szeszs; G St-Germain; L X Bonfietti; J Guarro; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

Review 3.  Are In Vitro Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia?

Authors:  Twisha S Patel; Peggy L Carver; Gregory A Eschenauer
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

4.  In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.

Authors:  M A Pfaller; M D Huband; R K Flamm; P A Bien; M Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

5.  Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Katyna Borroto-Esoda; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.

Authors:  Brunella Posteraro; Teresa Spanu; Barbara Fiori; Flavio De Maio; Elena De Carolis; Alessia Giaquinto; Valentina Prete; Giulia De Angelis; Riccardo Torelli; Tiziana D'Inzeo; Antonietta Vella; Alessio De Luca; Mario Tumbarello; Walter Ricciardi; Maurizio Sanguinetti
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

7.  Antifungal drug susceptibility and phylogenetic diversity among Cryptococcus isolates from dogs and cats in North America.

Authors:  Lisa M Singer; Wieland Meyer; Carolina Firacative; George R Thompson; Eileen Samitz; Jane E Sykes
Journal:  J Clin Microbiol       Date:  2014-04-02       Impact factor: 5.948

Review 8.  SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY.

Authors:  Ana Alastruey-Izquierdo; Marcia S C Melhem; Lucas X Bonfietti; Juan L Rodriguez-Tudela
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-09       Impact factor: 1.846

9.  Comparison of Two Commercial Colorimetric Broth Microdilution Tests for Candida Susceptibility Testing: Sensititre YeastOne versus MICRONAUT-AM.

Authors:  Sophie Philips; Frederik Van Hoecke; Emmanuel De Laere; Steven Vervaeke; Roos De Smedt; Jerina Boelens; Deborah De Geyter; Denis Piérard; Katrien Lagrou
Journal:  J Fungi (Basel)       Date:  2021-05-01

10.  Two echinocandin-resistant Candida glabrata FKS mutants from South Africa.

Authors:  Serisha D Naicker; Rindidzani E Magobo; Thokozile G Zulu; Tsidiso G Maphanga; Nkosinathi Luthuli; Warren Lowman; Nelesh P Govender
Journal:  Med Mycol Case Rep       Date:  2016-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.